Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zynex ( (ZYXIQ) ) has issued an announcement.
On January 22, 2026, Zynex’s board removed former chair Thomas Sandgaard from all positions with the company, canceled his unvested equity awards, and terminated his cash compensation after determining he violated the company’s Code of Business Conduct and Ethics, following his January 21, 2026 federal indictment on alleged healthcare and securities fraud-related offenses; the board simultaneously reduced its size from seven to six members and appointed CEO and director Steven Dyson as chair. In a statement issued the same day, Zynex emphasized that the indicted former executives no longer have roles in its operations, highlighted a six-month overhaul of leadership, compliance, billing practices, and controls, and underscored its extensive cooperation with regulators and its ongoing Chapter 11 reorganization in the Southern District of Texas, signaling an effort to rebuild trust and strengthen governance while pursuing a long-term resolution of investigations and its financial restructuring.
The most recent analyst rating on (ZYXIQ) stock is a Sell with a $0.08 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXIQ Stock Forecast page.
Spark’s Take on ZYXIQ Stock
According to Spark, TipRanks’ AI Analyst, ZYXIQ is a Underperform.
The score is driven primarily by weak financial performance (revenue collapse, losses, negative equity, and negative operating cash flow). Technicals also reflect strong downside momentum with the stock trading far below major moving averages. The earnings call reinforces significant liquidity and debt pressures, while valuation offers limited support due to negative earnings and no dividend.
To see Spark’s full report on ZYXIQ stock, click here.
More about Zynex
Zynex, Inc., founded in 1996 and based in Englewood, Colorado, is an innovative medical technology company that develops, manufactures, markets, and sells non-invasive medical devices for pain management and rehabilitation, with a focus on improving quality of life for patients suffering from debilitating pain and other conditions.
Average Trading Volume: 6,134,632
Technical Sentiment Signal: Sell
Current Market Cap: $2.57M
Learn more about ZYXIQ stock on TipRanks’ Stock Analysis page.